Rua Bioscience Asks Shareholders for More Cash — Again. Is This Survival or a Slow Bleed?

Shares of New Zealand medicinal cannabis company Rua Bioscience slid 12.5% to NZD 0.03 after the firm announced a deeply discounted rights issue — its third in roughly a year — raising urgent questions about whether the company can ever stand on its own financially.

• This Is the Third Rights Issue in Under a Year, and the Pattern Is Alarming. Rua previously raised NZD 3.1 million through a rights issue priced at NZD 0.025 — a 47.9% discount to its trading price at the time.

Before that, it launched a NZD 2 million raise at the same NZD 0.025 price, then a 35% discount. Now it is back again, offering one new share for every three held at NZD 0.025 , seeking up to NZD 2.8 million at a 32% discount to the 20-day average price. Serial dilution at bargain-basement prices signals a business burning cash faster than it can generate it.

• Revenue Is Growing Fast but Losses Barely Budge. FY26 total revenue rose 53% to NZD 2.9 million, with customer revenue up 71% to NZD 2.6 million. Yet the loss before tax was NZD 3.36 million — meaning Rua still spends more than a dollar for every dollar it earns. At the half-year mark, despite surging sales, the net loss improved only slightly because higher inventory financing costs and stock adjustments ate into gains. Until losses shrink meaningfully, every capital raise is a Band-Aid.

• The Company Is Betting on a Big UK Deal to Change the Math. After year-end, Rua secured its largest export agreement to date in the United Kingdom, expected to generate NZD 10 million over its initial two-year term.

The new funds are earmarked for working capital, inventory, and marketing to convert international opportunities — particularly in the UK, Germany, Australia, and Czechia — into revenue. That UK contract could be transformative, but shareholders are being asked to fund the bridge.

• The Self-Sustainability Promise Keeps Getting Deferred. Rua says that if fully subscribed, the rights offer plus expected proceeds from selling its Gisborne manufacturing facility should take the business to a self-sustaining position. It made a nearly identical claim in its prior raises. The company debuted on the NZX in 2020 at NZD 0.70 per share; it now trades at roughly NZD 0.03 — a 96% decline. With a market capitalization of around NZD 7.75 million, investors must decide whether the UK contract justifies yet another leap of faith.